Tziporah Cohen, MD, is an Instructor at Harvard Medical School and a Staff Psychiatrist at the Beth Israel Deaconess Medical Center, both located in Boston, Massachusetts, serving as the psycho-oncologist for the Cancer Care Center. She is a member of the American Psycho-Oncology Society and has a special interest in working with dying patients. Dr. Cohen attended Harvard Medical School and trained in adult psychiatry at The Cambridge Hospital, Cambridge, Massachusetts. She completed a fellowship in psycho-oncology at the Dana-Farber Cancer Institute in Boston.

Jay Nathanson, MD, MPH, graduated from the University of Western Ontario Medical School, in London, Ontario, Canada. He completed a residency in adult psychiatry and a fellowship in psychosomatic medicine at Boston University, Boston, Massachusetts. He has a Masters in Public Health, with a focus in health law and medical ethics, from the Boston University School of Public Health. In 2002-2003, he was a Fellow in medical ethics at Harvard Medical School in Boston. Dr. Nathanson is an Associate Professor of Psychiatry at both the University of Massachusetts Medical School and the Tufts University School of Medicine in Boston. He is currently the Psychiatric Liaison to the HIV and Infectious Disease Services at the Lemuel Shattuck Hospital in Boston.

Professor, Department of Psychiatry; Director, Clinical Neuroscience, Medical University South Carolina, Charleston, South Carolina

Email: bradyk@musc.edu

Kathleen Brady, MD, PhD, has disclosed that she has received grants for clinical research and served as an advisor or consultant for Pfizer, Abbott, Eli Lilly, Forest Laboratories, Bristol-Myers Squibb and GlaxoWellcome, Inc.

Associate Professor of Psychiatry, New York University School of Medicine; Staff Psychiatrist, Bellevue Hospital Center, New York, NY

Email: JimChou66@aol.com

James C.-Y. Chou, MD, has disclosed that he has received grants for clinical research and educational activities from Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Pfizer, Otsaka, Wyeth, Johnson & Johnson, Ortho-McNeil, Novartis, and AstraZeneca.

Professor Emeritus, University of Pittsburgh, Department of Psychiatry, Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania

Email: gershons@upmc.edu

Samuel Gershon, MD, has disclosed no relevant financial relationships.

Associate Professor of Medicine and Psychiatry, Tufts University School of Medicine, Boston, Massachusetts; Director, Center for Quality Assessment and Improvement in Mental Health (www.cqaimh.org) at the Tufts-NEMC Institute for Clinical Research and Health Policy Studies

Email: rhermann@cqaimh.org

He is a consultant to Pacificare Behavioral Healthcare and The Oakgroup (developers of MCAP utilization management criteria) and is a member of measurement advisory panels of the National Committee for Quality Assurance (NCQA), Joint Commission for the Accreditation of Healthcare Organizations (JCAHO), American Psychiatric Association, and National Quality Forum.

Professor of Psychiatry, Mount Sinai School Medicine; Director, Seaver and NY Autism Center of Excellence, Mount Sinai Hospital, New York, NY

Email: Eric.hollander@mssm.edu

Eric Hollander, MD, has disclosed that he has received grants for clinical research and educational activities from Abbott, Pfizer, Wyeth, and UCB Pharma and has served as an advisor or consultant for Abbott and Wyeth.

Professor, Vice Chairman for Research, Department of Psychiatry; Chief, Division of Clinical Neuroscience, University of Cincinnati Hospital, Cincinnati, Ohio

Email: Paul.keck@uc.edu

Paul E. Keck, Jr., MD, has disclosed that he is a consultant to or member of the scientific advisory boards of Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutica, Eli Lilly and Company, Novartis, Pfizer, Shire, and Wyeth. Dr. Keck is a principal or coinvestigator on research studies sponsored by Abbott Laboratories, the American Diabetes Association, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Elan, Eli Lilly and Company, Janssen Pharmaceutica, National Institute of Mental Health, National Institute of Drug Abuse, Organon, Ortho-McNeil, Pfizer, and UCB Pharma.

Professor and Director, Section on Psychosis, University of California at Los Angeles Neuropsychiatric Institute; Director, Desert Pacific Mental Illness Research, Education, and Clinical Center, US Department of Veterans Affairs

Email: marder@ucla.edu

Stephen R. Marder, MD, has disclosed that he has received grants for educational activities from Bristol-Myers Squibb and Otsuka. Dr. Marder has also disclosed that he served as an advisor to Bristol-Myers Squibb, Otsuka, Pfizer, and Solvay.

Director, Center for Anxiety and Traumatic Disorders, Massachusetts General Hospital; Associate Professor of Psychiatry, Harvard Medical School, Boston, Massachusetts

Email: mhpollack@bics.bwh.harvard.edu

Mark H. Pollack, MD, has disclosed that he has received grants for clinical research from Cephalon, Forest Laboratories, GlaxoSmithKline, Janssen, Eli Lilly, Pfizer, UCB Pharma, and Wyeth. He has also served as an advisor for Bristol-Myers Squibb, Cephalon, Forest Laboratories, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Otsuka Pharmaceuticals, Pfizer, Predix, Roche Laboratories, Sepracor, UCB Pharma, and Wyeth. Dr. Pollack is on the speakers' bureau for Forest Laboratories, GlaxoSmithKline, Janssen, Eli Lilly, Pfizer, UCB Pharma, and Wyeth.

Professor of Psychology, Hofstra University, Hempstead, New York

Email: William.C.Sanderson@hofstra.edu

William Sanderson, PhD, has disclosed no relevant financial relationships.